UBS has downgraded veterinary company Vimian to "sell," citing that its share price is currently perfect, with a target price of SEK 35. The firm notes that Vimian trades at a 70% premium to its sector, indicating the market expects near-perfect execution, which leaves little room for error. Additionally, UBS highlights risks in the company's momentum despite its recent double-digit organic growth.